The prognostic impact of complex karyotype in CLL is nuanced and not a simple high-risk flag. It's most significant with five or more abnormalities combined with other factors like a P53 mutation. Specific subtypes, such as those with trisomy 12 and 19, may not confer a poor prognosis.
For patients experiencing bothersome bruising on second-generation BTK inhibitors like zanubrutinib or acalabrutinib, the first-line management strategy should be dose reduction. Switching between agents is a secondary option. Zanubrutinib may offer more flexibility for these dose adjustments.
A negative Minimal Residual Disease (MRD) result is not a universal surrogate for Progression-Free Survival (PFS). Its predictive power is context-dependent; it's meaningful when comparing similar treatments (e.g., BTKi + BCL2i vs. another BTKi + BCL2i), but less so when comparing entirely different drug classes.
In complex, real-world CLL cases with elderly patients and comorbidities, the 'art of medicine' prevails. Opting for a less intensive, guideline-deviant therapy like single-agent obinutuzumab can be a reasonable choice to control symptoms and improve quality of life, prioritizing safety over maximal PFS.
The combination of a Notch1 mutation and a specific IGHV stereotype (439 subset 8) creates an extremely high risk for early Richter's transformation in CLL. This finding warrants consideration of immediate combination therapy, even if the patient doesn't meet standard treatment criteria.